Professional
Added to YB: 2024-10-28
Pitch date: 2024-09-30
VCYT [bullish]
Veracyte, Inc.
+26.6%
current return
Author Info
No bio for this author
Company Info
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
Market Cap
$3.1B
Pitch Price
$33.84
Price Target
N/A
Dividend
N/A
EV/EBITDA
32.57
P/E
103.44
EV/Sales
5.62
Sector
Biotechnology
Category
growth
Artisan Small Cap Fund Portfolio Holding: Veracyte, Inc.
VCYT: Diagnostic co. combines RNA sequencing, ML & 'field of injury' tech. 23% test vol growth, 27% rev growth, 21% EBITDA margin. Potential for annuity-like revenue. New genetic tests for prostate/thyroid cancer could reduce surgeries & health costs. Shares rebounded on strong earnings.
Read full article (1 min)